Moderna, Merck mRNA cancer vaccine nears breakthrough; shares surge 180%

Moderna shares jumped 180% on reports that its mRNA cancer vaccine, developed with Merck, is nearing a breakthrough. The claim is based on a single translated news item and lacks corroborating detail on trial data or regulatory milestones. If confirmed, this would mark a major advance in personalized oncology and a significant commercial catalyst for Moderna.